News from ESMO 2025

From 17th - 21st October 2025, oncology professionals from around the world converge at the European Society for Medical Oncology congress in Berlin, Germany. Read some of the new research findings that scientists and clinicians from the ICR and The Royal Marsden showcased this year.

Xenopus cancer kidney cells interphase Paul Andrews 945x532
International trial shows combination immunotherapy treatment significantly improves survival in high-risk kidney cancer patients

21/10/25

Combination immunotherapy treatment significantly improves disease-free survival following surgery in patients with the most common type of kidney cancer, according to new research.
See full story
MRI scan of a breast tumour
Targeted drug prolongs survival in breast cancer patient group

20/10/25

Patients with HR+ and HER2- node positive high-risk early breast cancer experience improved long term overall survival seven years on, following two years of taking a targeted drug alongside standard hormone therapy, according to new research.
See full story
Image of hand holding syringe
‘Smart jab’ shows promise in treating advanced head and neck cancer

19/10/25

A new type of cancer treatment which is given via an injection under the skin has shown early signs of success in patients with advanced head and neck cancer.
See full story
Purple lung cancer cells
New drug shows dramatic effect in shrinking lung cancer tumours

17/10/25

A new drug is having a dramatic effect on shrinking lung cancer tumours, according to new research.
See full story
MRI scan before bladder cancer surgery shown to save lives

17/10/25

Giving patients with suspected bladder cancer an MRI scan before surgery could mean they would be treated more quickly, leading to fewer deaths due to the disease, new ICR-led research suggests.
See full story
Prostate cancer cell spheroid 945x532px
Men with BRCA1 and BRCA2 gene mutations should get annual prostate cancer screening

16/10/25

Prostate cancer guidelines should change so that all men from the age of 40 with mutations in either the BRCA1 or BRCA2 gene are offered regular PSA testing to detect early signs of the disease, experts are urging.
See full story
If you’re a journalist and want to find out more, you can contact our media relations team.

Make a donation today

A monthly gift can help support our research over several years, so it has the maximum possible benefit for people with cancer.
With Gift Aid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

With your generous support, we can continue making more discoveries, finding more cures, and saving more lives.
With Gift Aid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

Our research centres & divisions

Through our close partnerships with The Royal Marsden and other key UK institutions, we're leading a wide breadth of cancer research across eight divisions and more than 25 research centres and strategic initiatives.
Centres and strategic collaborations Our divisions